Morphine is a widely used analgesic in humans that is associated with multiple untoward effects, such as addiction and physical dependence. In rodent models, morphine also induces locomotor activity. These effects likely involve functionally selective mechanisms. Indeed, G protein-coupled receptor desensitization and adaptor protein b-arrestin 2 (barr2) through its interaction with the m-opioid receptor regulates the analgesic but not the rewarding properties of morphine. However, barr2 is also required for morphine-induced locomotor activity in mice, but the exact cellular and molecular mechanisms that mediate this arrestin-dependent behavior are not understood. In this study, we show that barr2 is required for morphine-induced locomotor activity in a dopamine D1 receptor (D1R)-dependent manner and that a barr2/phospho-ERK (barr2/pERK) signaling complex may mediate this behavior. Systemic administration of SL327, an MEK inhibitor, inhibits morphine-induced locomotion in wild-type mice in a dose-dependent manner. Acute morphine administration to mice promotes the formation of a barr2/pERK signaling complex. Morphine-induced locomotor activity and formation of the barr2/pERK signaling complex is blunted in D1R knockout (D1-KO) mice and is presumably independent of D2 dopamine receptors. However, D1Rs are not required for morphine-induced reward as D1-KO mice show the same conditioned place preference for morphine as do control mice. Taken together, these results suggest a potential role for a D1R-dependent barr2/pERK signaling complex in selectively mediating the locomotor-stimulating but not the rewarding properties of morphine.
INTRODUCTION
Morphine binds to and activates m-opioid G proteincoupled receptors (GPCRs) in the brain and the spinal cord (Sora et al, 1997) . In addition to its anti-nociceptive properties, morphine is also addictive, thereby complicating its usage (von Zastrow, 2004) . The addictive properties of morphine have been attributed to its ability to activate m-opioid receptors on midbrain GABAergic interneurons, leading to a disinhibition of dopamine (DA) neurons in the ventral tegmental area , thus resulting in increased DA release in the dorsal and ventral striatum (Di Chiara and Imperato, 1988a, b; Johnson and North, 1992) . DA released in the striatum activates GPCRs on medium spiny neurons (MSNs) belonging to the D1 and D2 family of dopamine receptors and can regulate various behaviors, such as reward, locomotion, and cognition (Missale et al, 1998) .
GPCR signaling in the brain is terminated, at least in part, by a process termed 'desensitization' and is mediated by the concerted action of GPCR kinases (GRKs) and b-arrestins . In addition to desensitization, b-arrestins mediate the internalization of receptors and have also been shown to promote signaling through their ability to scaffold signaling molecules (Ferguson et al, 1996; Lefkowitz and Shenoy, 2005) . The desensitization properties of b-arrestins are important for morphine-induced antinociception but not for tolerance or reward in mice (Bohn et al, 1999 (Bohn et al, , 2002 (Bohn et al, , 2003 . In addition to anti-nociception, morphine also stimulates hyperlocomotor activity in mice in a dose-dependent manner (Bohn et al, 2003) , and chronic morphine administration induces locomotor sensitization, which is considered to be implicated in drug addiction (Becker et al, 2001) . The arrestin-dependent molecular mechanisms that regulate the manifestation of this hyperlocomotor behavior are unknown. Previous studies have implicated the cAMP/PKA/DARPP-32 signaling pathway as a potential mediator of the locomotor-stimulating effects of morphine in mice (Borgkvist et al, 2007) . Although there are significant changes in DARPP-32 phosphorylation after acute morphine administration, the hyperlocomotor activity observed in DARPP-32 knockout (KO) or DARPP-32 T34A mice is not completely abolished, suggesting that additional signaling pathways might have a role in the manifestation of this behavior. Interestingly, locomotor activation to drugs of abuse such as amphetamine and morphine, but not cocaine and PCP, are blunted in b-arrestin 2 KO (barr2-KO) mice, suggesting a role for b-arrestin signaling complexes in mediating the behavioral effects of certain drugs (Beaulieu et al, 2005; Bohn et al, 2003) (T. Daigle, unpublished observations). Although barr2 is required for morphineinduced locomotor activation but not for its rewarding properties, the biochemical mechanisms and the role of different dopamine receptors that regulate this behavior are not known.
In this study, we used a combination of genetic mouse models and biochemical techniques to investigate the role of b-arrestin-dependent signaling in the manifestation of morphine-induced locomotor activity in mice and the potential molecular determinants. Our study suggests that a barr2/phospho-ERK (barr2/pERK) signaling complex through the activation of the dopamine D1 receptor (D1R) may mediate the locomotor-enhancing action of morphine but not its rewarding properties.
MATERIALS AND METHODS

Animals and Drugs
All mouse studies were conducted in accordance with the NIH guidelines for animal care and use and with an approved animal protocol from the Duke University Animal Care and Use Committee. Generation of the dopamine transporter KO (DAT-KO), barr2-KO, barr1-KO, dopamine receptor 1 KO (D1-KO), and dopamine receptor 2 KO (D2-KO) mice and GSK3b + /À mice have been described previously (Bohn et al, 2003; Conner et al, 1997; Drago et al, 1994; Giros et al, 1996; Hoeflich et al, 2000; Kelly et al, 1997) . Experimental mice were obtained by crossing heterozygotes to obtain wild-type (WT) and KO littermates. For biochemical and behavioral experiments with small molecule inhibitors, WT C57Bl/6J mice (The Jackson Laboratory, Bar Harbor, ME) were used. All mice were housed at a maximum of five per cage, provided with food and water ad libitum, and tested at 12-20 weeks of age. Mice were age and gender matched, and all experiments were conducted in drug-naive animals. Morphine sulfate, raclopride, and SCH23390 were purchased from Sigma (St Louis, MO) and freshly prepared in saline (Sal); TDZD (GSK3 inhibitor) and SL327 (MEK inhibitor) were purchased from Tocris Biosciences (Ellisville, MO), were dissolved in minimal Tween-20, and brought up to volume with distilled water. All drugs were injected at a volume of 10 ml/g animal weight.
Locomotor Activity Measurements
Activity was measured in an Accuscan activity monitor (Accuscan Instruments, Columbus, OH) and was performed as described previously (Bohn et al, 2003) . In brief, locomotor activity was measured at 5-min intervals, and data were analyzed for the total distance traveled in 5-min increases for 150 min. Drugs were administered at various time points depending on the experimental paradigm and are described in the figure legends.
Immunoprecipitation and Western Blot Studies
Mice were injected with morphine (20 mg/kg) and then killed 60 min later. The striatum (caudate) was isolated using a rapid head-freeze dissection technique as described previously (Beaulieu et al, 2005) . Tissue samples were manually digested in cold 1% Triton X-100 lysis buffer, and lysates were incubated overnight with immobilized antipERK 1/2 beads (Cell Signaling Technology) for coimmunoprecipitation (co-IP) studies. Beads were washed thoroughly, boiled in Laemmli buffer, and co-immunoprecipitated proteins were analyzed by western blot. For western blot analysis, the immunoprecipitated proteins were loaded into 10% SDS-PAGE gels (Invitrogen), transferred onto nitrocellulose membranes, and incubated with antibodies to barr2 (gift from Dr RJ Lefkowitz, Duke University), DARPP-32, and pERK 1/2 (Cell Signaling Technology) to determine interactions with pERK. Blots were developed using the LICOR detection system (Licor Biosciences, Lincoln, NE). barr2 band intensity was measured using NIH ImageJ software and was normalized to pERK 1/2 intensity, which was used as a loading control.
Conditioned Place Preference
A conditioned place preference (CPP) apparatus from Med Associates (St Albans, VT) was used to analyze place preference to morphine in mice and was performed as described previously (Bohn et al, 2003) . In brief, the CPP procedure consisted of day 1 of pre-conditioning (pre-test), wherein mice were allowed to move freely between all chambers of the CPP apparatus and the time spent (basal preference) in each chamber was recorded for 30 min. In the conditioning phase, mice were injected with morphine (3 or 6 mg/kg) on days 2, 4, and 6 and with saline (Sal) on days 3, 5, and 7, and the drug was randomly paired with alternating compartments, such that half of the mice received drug in the black compartment and the other half in the white compartment. On day 8, the test day (test), mice were handled similar to the pre-conditioning day and allowed to move freely between all chambers, and the time spent (drug-induced preference) in each chamber was recorded for 30 min. The data were analyzed by calculating the difference (D) in time spent in the drug-paired chamber on the pre-test and test days.
Statistical Analyses
Data were analyzed by a standard two-way ANOVA test for comparison between genotypes, treatments, or doses. Individual genotypes, treatments, or doses were compared using a post hoc Tukey's test. Data are presented as mean±SEM.
RESULTS
Role of b-Arrestins in Morphine-Induced Locomotor Activation
b-Arrestins have two major isoforms, 1 and 2, and both have redundant and specific physiological roles (DeWire et al, 2007). Previously, it was shown that barr2 is required for morphine-induced locomotor activity (Bohn et al, 2003) , but the role of barr1 was not determined. We first confirmed the previously published result that barr2 is indeed required for morphine-induced locomotion. Locomotor activity of WT and barr2-KO mice was analyzed for an initial 30-min habituation period after which morphine (20 mg/kg, s.c.) was administered and activity analyzed for an additional 120 min. In this study, we chose to use a 20 mg/kg dose of morphine as it elicits a robust locomotor response, which is significantly blunted in barr2-KO mice (Bohn et al, 2003) , but does not show a differential gastrointestinal or respiratory suppression response between the two genotypes (Raehal et al, 2005) . WT mice showed a robust time-dependent increase in locomotor activity after morphine administration (20 mg/kg, s.c.), which was blunted in barr2-KO mice (Supplementary Figure S1) . As observed before, morphineinduced cumulative distance traveled over a period of 150 min was significantly decreased in barr2-KO mice than in WT littermate controls ( Figure 1a ). However, in barr1-KO mice, morphine-induced (20 mg/kg, s.c.) locomotor activity was not significantly different than in WT littermate controls (Figure 1b ), even at lower doses (data not shown). These data suggest that barr2 is the major isoform that regulates morphine-induced locomotor activity and that barr1 does not compensate for the loss of barr2 function.
ERK is Required for Morphine-Induced Locomotor Activity
Previous work from our laboratory has suggested a role for a barr2/AKT/GSK3 signaling complex in amphetamineinduced locomotion in mice (Beaulieu et al, 2005) . Therefore, we asked the question whether this signaling complex could also regulate morphine-induced locomotor activity. We used both genetic and pharmacological manipulation of GSK3b to answer this question. In mice that are heterozygote for the GSK3b gene (GSK3b + /À) or WT mice systemically treated with the GSK3 inhibitor TDZD, amphetamine-induced locomotor activity is inhibited (Beaulieu et al (2004) and Supplementary Figure S2c) . Surprisingly, morphine-induced locomotion was not inhibited in either GSK3b + /À mice (Supplementary Figure  S2a) or WT mice treated with TDZD (30 mg/kg, i.p.) (Supplementary Figure S2b) compared with their vehicle controls. However, morphine-induced locomotion was increased in GSK3b + /À mice (Supplementary Figure  S2b) . These results suggest that the barr2/AKT/GSK3 signaling complex may not have a major role in the regulation of morphine-induced locomotor activity.
Several studies have shown an important role for ERK signaling in the behavioral effects of morphine (Liu et al, 2007; Valjent et al, 2006a b) . We asked whether ERK signaling might be involved in the regulation of morphine-induced locomotor activity. To answer this question, we used the MEK inhibitor SL327, which has been shown to inhibit ERK activity in the brain (Beaulieu et al, 2006) . WT mice were pre-treated with SL327 for 15 min after which they were administered an acute dose of morphine (20 mg/ kg, s.c.) and their locomotor activity was measured. SL327 inhibited morphine-induced locomotor activity in a dosedependent manner (Figure 2b ), suggesting a role for ERK signaling in the locomotor effects of morphine.
Acute Morphine Administration Leads to Formation of a b-arr2/pERK Signaling Complex b-Arrestins have been shown to scaffold signaling complexes and engage a mode of signaling that is distinct from G protein-mediated signaling both in terms of kinetics and spatial pattern (Lefkowitz and Shenoy, 2005) . In particular, b-arrestins have been shown to scaffold ERK signaling complexes, which have distinct physiological outcomes compared with G protein-mediated signaling Wei et al, 2004) . As morphine-induced locomotor activity is inhibited in barr2-KO mice and by MEK/ERK inhibition, we therefore asked whether barr2/ERK signaling complexes are formed during morphine-induced locomotion and also whether this complex might mediate this behavior. WT mice were acutely administered with morphine (20 mg/kg, s.c.), and 60 min later the brains were processed for co-IP of barr2/ERK complexes (see the 'Materials and methods' section). As shown in Figure 3 , morphine administration results in a three-fold increase in the formation of the barr2/pERK complex over basal, but DARPP-32 does not co-immunoprecipitate with pERK. These results suggest that morphine regulates barr2/pERK signaling complexes in the striatum, which may have a role in morphine-induced locomotor activity and that DARPP-32 is not involved in this b-arrestin signaling complex. Some studies have implicated D1 dopamine receptors in mediating morphine-induced locomotor activity (Becker et al, 2001; Borgkvist et al, 2007) . D1 receptors activate the canonical PKA/DARPP-32 pathway through coupling to Gas that activates adneylate cyclase leading to cAMP accumulation (Greengard, 2001; Missale et al, 1998) . Therefore, we examined whether D1 receptors were required for b-arrestin-dependent locomotion induced by morphine. To investigate this question, we initially tested the ability of morphine to induce locomotor activity in D1-KO mice. D1-KO mice and their WT littermates were injected acutely with morphine at different doses (Figure 4a and b). WT mice displayed a robust locomotor response to morphine at doses of 5, 10, and 20 mg/kg s.c., whereas D1-KO mice displayed a significantly blunted response at all three doses (Figure 4b) . Similarly, acute inhibition of D1R function using the receptor antagonist SCH23390 resulted in the inhibition of morphine-induced locomotion (Supplementary Figure S3 , black bars). To further address the question whether D1 receptors regulate morphine-induced locomotion in a b-arrestin-dependent manner, we performed co-IPs of pERK and barr2 in control (WT) and D1-KO mice. As shown in Figure 5 , pERK and barr2 co-immunoprecipitated together in WT (1.5-fold over saline) but not in D1-KO mice, suggesting a role for D1 receptors in mediating morphine-induced barr2/pERK complex formation. As a control, we also assessed the effect of inhibition of D2 receptor function on morphine-induced locomotion using both genetic and pharmacological approaches. Surprisingly, morphine-induced locomotion was also significantly reduced in either D2-KO mice compared with their WT littermates (Figure 4c ) or by administration of the D2R antagonist raclopride to WT mice (Supplementary Figure S3, gray bars) . However, as the function of the pre-synaptic D2 receptor is also inhibited in both D2-KO mice and WT mice treated with raclopride, the reduction of morphine-induced locomotion in these mice could be a result of a dysregulation of pre-synaptic D2 receptor function and subsequent DA release (Rouge-Pont et al, 2002) . Furthermore, ablation of only the post-synaptic D2 long isoform in mice (D2L-KO) does not alter the locomotor-inducing effects of morphine (Smith et al, 2002) . Taken together, these studies suggest that D2 receptors may not have a critical role in morphine-induced locomotion. To further investigate the exact contribution of D2 receptors in morphine-induced locomotion, we used DAT-KO mice. DAT-KO mice have elevated extracellular levels of DA due to the absence of DA uptake by DAT and exhibit hyperlocomotion (Giros et al, 1996) . In addition, these mice have a loss of pre-synaptic D2 receptor function (Jones et al, 1999) , making them an ideal model to assess the postsynaptic D2 receptor contribution to morphine-induced 
D1 Receptors are Not Required for the Rewarding Properties of Morphine
Previous work from our laboratory has shown that barr2 is not required for morphine locomotor sensitization, whereas CPP to morphine was increased in barr2-KO mice than in WT littermates (Bohn et al, 2003) . Interestingly, in D1-KO mice, sensitization to morphine is inhibited (Becker et al, 2001) . Therefore, we examined whether D1-KO mice could experience the rewarding effects of morphine. To answer this question, we assessed the ability of WT and D1-KO mice to show place preference to morphine. Surprisingly, both WT and D1-KO mice showed morphine-induced CPP at doses of 3 and 6 mg/kg s.c. (Figure 6 ). These and previous 
DISCUSSION
b-Arrestins are classically known to mediate desensitization and internalization of receptors, but recently they have been shown to promote G protein-independent signaling through their ability to scaffold various signaling molecules (Beaulieu et al, 2009; Lefkowitz and Shenoy, 2005) . Previously, we have shown that in barr2-KO mice, the analgesic and rewarding properties of morphine are enhanced, suggesting a role for the desensitizing function of barr2 in limiting these responses (Bohn et al, 1999 (Bohn et al, , 2003 . Interestingly, the locomotor-enhancing effects of morphine are blunted in barr2-KO but not in barr1-KO mice (Figure 1) , suggesting a role for barr2-dependent signaling in the regulation of morphine-dependent locomotion. In this study, we sought to determine the molecular mechanism of this barr2-dependent morphine-induced locomotor activity. We show that barr2 interaction with pERK increases in the striatum on morphine stimulation (Figure 3 ) and that this barr2/pERK signaling complex may mediate morphine-induced locomotion. Previous studies from our laboratory with barr2-KO mice have shown a role for a barr2/AKT/GSK3b signaling complex that mediates DAdependent behaviors, such as locomotion (Beaulieu et al, 2005) . Although we show that morphine-induced locomotion does not require GSK3b, an important point to be noted is that studies showing a role for barr2/AKT/GSK3b in DA-dependent behaviors were conducted with amphetamine and thus could represent the activation status of different receptors as compared with morphine stimulation. Amphetamine-induced b-arrestin complex formation requires mostly D2 receptors (Beaulieu et al, 2007) , whereas morphine-induced complex formation primarily requires D1 receptors (Figures 4 and 5) . b-Arrestins are known to scaffold MAPK signaling molecules to mediate ERK activation . Although ERK is required for previously learned place preference induced by cocaine and morphine (Valjent et al, 2006a) , it is not required for acute locomotor effects of amphetamine and cocaine as shown by inhibiting ERK activation using the MEK inhibitor SL327 (Valjent et al, 2006b ). However, amphetamine-induced locomotion can be inhibited by administration of high doses of SL327 (Beaulieu et al, 2006) , suggesting that ERK signaling might have a role in the acute locomotor effects of certain psychostimulants. Unexpectedly, morphine-induced locomotion is also inhibited by SL327 administration in a dosedependent manner (Figure 2 ) consistent with a barr2/pERK signaling complex mediating morphine-induced locomotion. Interestingly, even at high doses of SL327 (50 and 100 mg/kg), cocaine-induced hyperlocomotion is not significantly inhibited (data not shown), highlighting the specificity of the inhibition of morphine-induced locomotion. Furthermore, this barr2/pERK complex does not form in D1-KO mice on morphine stimulation and morphineinduced locomotion is significantly inhibited in D1-KO mice in a dose-dependent manner (Figures 4 and 5) . Our results are consistent with previous findings that the D1 receptor forms a complex with pERK and barr2 in cultured SK-N-MC neuroblastoma cells (Chen et al, 2004) . Thus, collectively, these data suggest that a D1R/barr2/pERK complex may mediate morphine-induced locomotion.
A previous study by Becker et al (2001) showed that D1 receptors are critical for developing locomotor sensitization b-Arrestin signaling mediates morphine-induced locomotion NM Urs et al to morphine in mice. Locomotor sensitization is presumably related to the rewarding properties of a drug but surprisingly D1 receptors are not required for CPP to morphine (Figure 6 ), suggesting that D1 receptors are required for acquisition of sensitization but not for the expression of reward in CPP. In addition, Becker et al (2001) also showed that m-opioid receptor expression in the striatum of D1-KO mice is reduced. The m-opioid receptors are expressed on both MSNs of the striatum and on GABAergic interneurons of the midbrain. Although the ability of morphine to enhance the release of DA from midbrain DA neurons is presumably required for striatal D1R activation, the exact contribution of striatal m-opioid receptors to the locomotor effects of morphine is not known. Interestingly, Juhasz et al (2008) showed in HEK cells that m-opioid and D1 receptors form hetero-oligomers and that m-opioid receptor expression was increased in the presence of D1 receptors and this effect required the Cterminal region of the D1 receptor. Therefore, it is possible that D1 and m-opioid receptors in the striatum work in concert to mediate the effects of morphine. In addition, a study by Zhang et al (1998) showed that m-opioid receptors that normally do not recruit b-arrestins on morphine stimulation can recruit barr2 on overexpression of GRK2. However, Haberstock-Debic et al (2005) have shown that unlike HEK cells, morphine stimulation can lead to m-opioid receptor binding to b-arr2 and internalization in rat striatal neurons. Therefore, it is also possible that D1 receptors in the striatum act as a GRK/b-arrestin recruitment-promoting agent for the m-opioid receptor. Thus, in addition to the ability of morphine to release DA from midbrain neuron projections, a possible scenario is that simultaneous binding of morphine to m-opioid receptors and that of DA to D1 receptors in the striatum results in morphine-dependent b-arrestin signaling. It would be interesting to study the effect of selective ablation of m-opioid receptors in D1 receptor expressing MSNs of the striatum. If indeed the D1 and m-opioid receptors heterodimerize in vivo and are both required in MSNs for morphine-induced locomotion, then one would expect that deletion of the m-opioid receptor in D1 expressing MSNs would lead to inhibition of morphine-induced locomotion, without altering the rewarding or analgesic properties of morphine. Taken together, these data provide evidence for the formation of a barr2/pERK signaling complex mediated by the activation of the D1 receptor that may potentially have a role in regulating morphine-induced locomotion. However, this D1R and barr2-dependent signaling pathway does not have a role in the rewarding properties of morphine highlighting a functional selectivity (Urban et al, 2007) of signaling pathways at these receptors.
